For Patients
When deciding to participate in the trial, please, contact the study coordinators of one of the two clinical sites directly to see if you are eligible for the trial: A multicenter, open label cohort Phase 1 dose escalation study to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PF-114 mesylate for oral administration in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), which is resistant to the 2-nd generation Bcr-Abl inhibitors or has T315I mutation in the BCR-ABL gene. The information on the Study is listed on registry and results database of publicly and privately supported clinical studies of human participants conducted around the world — the

Please, see the Informed Consent Form to participate in the Clinical Tria
National Research Center for Hematology
Russia, 125 167, Moscow, Novii Zikovskii pr., 4

Principal Investigator:
Prof. DMSci Anna Turkina — Head of Myeloproliferative diseases
Clinical Study Coordinator:
Oleg Shuhov MD, PhD

[email protected]
+7 985 287 12 69
Federal Almazov North-West Medical Research Centre
Russia, 197 341, St. Petersburg, Akkuratova st., 2

Principal Investigator:
Elza Lomaia MD, PhD, — lead scientist of Onco-hematology Department
[email protected]
+7 981 936 16 67
Moscow City Centre of Hematology based on City Hospital named by S.Botkin
5, 2-nd Botkin's lane, build. 17, entrance 3
125284 Moscow

Principal Investigator:
Prof. DMSci Olga Vinogradova — Head of Moscow City Centre of Hematology

[email protected]
tel. +7(495)945-97-61

Made on